Who founded Ensysce Biosciences?

Ensysce Biosciences was founded by D. Lynn Kirkpatrick, PhD, Dr. Bob Gower.

How much funding has Ensysce Biosciences raised?

Ensysce Biosciences has disclosed $102.6M raised across 8 rounds.

Where is Ensysce Biosciences headquartered?

Ensysce Biosciences is headquartered in La Jolla, US.

Ensysce Biosciences

NASDAQ: ENSC

La Jolla, US · Delaware corporation

Find your way into Ensysce Biosciences

Paths you didn't know you had: your email and LinkedIn already hold routes to the Ensysce Biosciences team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Ensysce is a pharmaceutical development company focused on developing safer medicines, with particular expertise in pain management and opioid-related drug development. The team has extensive experience bringing targeted small molecule drugs and oncology compounds from discovery through clinical development to market approval.

Biotech Healthtech Medical Devices

Founders & leadership

D. Lynn Kirkpatrick, PhDCo-founder

Dr. Bob GowerFounder and Chairman

James MorrisonExecutive

D. Lynn Kirkpatrick CEOKirkpatrick has co-founded two biotech companies and led discovery and clinical development of three targeted small molecule oncology drugs into Phase 2 testing. As executive officer and director of Ensysce Biosciences, he oversees development of safer opioid medications for severe pain management.

Dave Humphrey Chief Financial OfficerDave Humphrey is Chief Financial Officer at Ensysce Biosciences, a pharmaceutical development company focused on safer medicines and opioid-related drug development. He has held CFO positions at bioscience companies ranging from private startups to public firms, with expertise in corporate strategy, financing, investor relations, and SEC reporting.

Linda Pestano Chief Development OfficerShe has experience designing preclinical programs and building IND-enabling data packages for drug candidates targeting cancer and inflammatory diseases.

Linda Pestano, PhD

Dr. William Schmidt, PhD

Lynn Kirkpatrick CEOLynn Kirkpatrick co-founded two biotech companies and has experience discovering and developing targeted small molecule oncology drugs through Phase 2 clinical development. He has directed early discovery, development, and clinical evaluations at both private and public companies, and now leads Ensysce Biosciences as President and CEO, focusing on developing safer opioid medicines for severe pain management.

Geoffrey BirkettChief Commercial Officer

Jeffrey MillardChief Operating Officer (consultant)

William Schmidt Chief Medical OfficerWilliam Schmidt is Chief Medical Officer of Ensysce Biosciences, a pharmaceutical development company focused on safer medicines in pain management and opioid-related drug development.

Reported raises · per SEC filings

Form D private placements

$102.6M disclosed across 8 rounds · 2021–2026

▶$77.2MraisedAug 2026 · 44 investors · Other Health Care

Rule 506(b)